Blair William & Co. IL Has $4.71 Million Position in GlaxoSmithKline plc (GSK)

Blair William & Co. IL increased its stake in GlaxoSmithKline plc (NYSE:GSK) by 15.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 117,277 shares of the pharmaceutical company’s stock after purchasing an additional 15,615 shares during the quarter. Blair William & Co. IL’s holdings in GlaxoSmithKline were worth $4,711,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. grew its position in GlaxoSmithKline by 31.1% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 261,744 shares of the pharmaceutical company’s stock worth $10,551,000 after purchasing an additional 62,159 shares during the period. TD Asset Management Inc. grew its position in GlaxoSmithKline by 1.7% in the 2nd quarter. TD Asset Management Inc. now owns 146,562 shares of the pharmaceutical company’s stock worth $5,908,000 after purchasing an additional 2,457 shares during the period. TCW Group Inc. grew its position in GlaxoSmithKline by 11.5% in the 2nd quarter. TCW Group Inc. now owns 56,996 shares of the pharmaceutical company’s stock worth $2,298,000 after purchasing an additional 5,900 shares during the period. D.A. Davidson & CO. grew its position in GlaxoSmithKline by 4.6% in the 2nd quarter. D.A. Davidson & CO. now owns 171,827 shares of the pharmaceutical company’s stock worth $6,926,000 after purchasing an additional 7,500 shares during the period. Finally, Wellington Shields & Co. LLC grew its position in GlaxoSmithKline by 12.2% in the 2nd quarter. Wellington Shields & Co. LLC now owns 13,350 shares of the pharmaceutical company’s stock worth $538,000 after purchasing an additional 1,450 shares during the period. 10.97% of the stock is currently owned by hedge funds and other institutional investors.

Shares of GSK stock opened at $38.61 on Tuesday. GlaxoSmithKline plc has a 1 year low of $34.52 and a 1 year high of $42.36. The company has a quick ratio of 0.63, a current ratio of 0.95 and a debt-to-equity ratio of 6.66. The firm has a market cap of $103.83 billion, a PE ratio of 13.41, a price-to-earnings-growth ratio of 2.81 and a beta of 0.81.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 31st. The pharmaceutical company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.03). GlaxoSmithKline had a net margin of 5.78% and a return on equity of 164.99%. The business had revenue of $9.41 billion for the quarter, compared to the consensus estimate of $10.55 billion. On average, sell-side analysts forecast that GlaxoSmithKline plc will post 2.98 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 10th. Stockholders of record on Friday, November 16th will be given a dividend of $0.486 per share. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Thursday, November 15th. This represents a $1.94 dividend on an annualized basis and a dividend yield of 5.03%. GlaxoSmithKline’s payout ratio is presently 67.36%.

GSK has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research report on Wednesday, November 28th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, September 25th. Wolfe Research initiated coverage on shares of GlaxoSmithKline in a research report on Tuesday, October 23rd. They issued a “market perform” rating for the company. ValuEngine raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research report on Friday, October 19th. Finally, Liberum Capital downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, August 30th. Ten analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $43.00.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2018/12/04/blair-william-co-il-has-4-71-million-position-in-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: What is systematic risk?

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit